{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:20:45Z","timestamp":1788952845208,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26460217"],"award-info":[{"award-number":["JP26460217"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lambert\u2010Eaton myasthenic syndrome (LEMS) is characterized by muscle weakness, amyotrophy, easy fatigability, and depressed tendon reflexes. 3,4\u2010Diaminopyridine (3,4\u2010DAP) is the recommended therapy for the treatment of LEMS. However, estimations of 3,4\u2010DAP pharmacokinetics in human and animals, such as rats, are rarely reported because 3,4\u2010DAP is an orphan drug for the treatment of a very rare disease (LEMS). In particular, little is known about its tissue distribution. Therefore, the pharmacokinetics of 3,4\u2010DAP were studied, with particular focus on tissue distribution, in rats. After intravenous administration of 3,4\u2010DAP to rats, the half\u2010life of 3,4\u2010DAP was 15.9\u00a0\u00b1\u00a03.9\u00a0min and the volume of distribution at steady\u2010state was 2.8\u00a0\u00b1\u00a00.7\u00a0L\/kg. The tissue\u2010to\u2010plasma partition coefficient (Kp) was high in the kidney, heart, and muscle. In addition, with increased steady state plasma concentration (Css), a tendency toward increased Kp was found in most tissues. In the muscle, a likely target region of 3,4\u2010DAP in LEMS patients, the Kp was higher than in the plasma. Furthermore, more than 68% of 3,4\u2010DAP was distributed to the muscle as determined by the ratio of 3,4\u2010DAP distribution calculated from the apparent volumes of distribution. Hence, 3,4\u2010DAP may provide for more effective and long\u2010lasting effects.<\/jats:p>","DOI":"10.1002\/bdd.2203","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T20:47:39Z","timestamp":1565988459000},"page":"294-301","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics and tissue distribution of 3,4\u2010diaminopyridine in rats"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3011-3714","authenticated-orcid":false,"given":"Natsuko","family":"Ishida","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University  Kakuma\u2010machi Kanazawa Ishikawa 920\u20101192 Japan"},{"name":"Department of Clinical Research, Iou National Hospital National Hospital Organization  Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Kondo","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University  Kakuma\u2010machi Kanazawa Ishikawa 920\u20101192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Chikano","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University  Kakuma\u2010machi Kanazawa Ishikawa 920\u20101192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erina","family":"Kobayashi\u2010Nakade","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University  Kakuma\u2010machi Kanazawa Ishikawa 920\u20101192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Suga","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University  Kakuma\u2010machi Kanazawa Ishikawa 920\u20101192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University  Kakuma\u2010machi Kanazawa Ishikawa 920\u20101192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonobu","family":"Komai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hokuriku Brain and Neuromuscular Disease Center, Iou National Hospital National Hospital Organization  Ishikawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4333-7167","authenticated-orcid":false,"given":"Ryo","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University  Kakuma\u2010machi Kanazawa Ishikawa 920\u20101192 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(96)00012-3"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(94)00225-D"},{"key":"e_1_2_8_4_1","volume-title":"Physical Methods in The Chemistry of Heterocyclic Compounds","author":"Albert A.","year":"1963"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270411"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1211\/002235702320402080"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/js960113"},{"key":"e_1_2_8_8_1","unstructured":"European Medicines Agency(2009).European Public Assessment Reports.https:\/\/www.ema.europa.eu\/documents\/assessment\u2010report\/firdapse\u2010epar\u2010public\u2010assessment\u2010report_en.pdf#search=%27zenas+Assessment+Reports%27.pdf(accessed 12 July 2019)"},{"key":"e_1_2_8_9_1","unstructured":"European Medicines Agency(2014).Product Information.http:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2018\/20180713141881\/anx_141881_en.pdf#search=%27Firdapse+EMA+assessment+report%27.pdf(accessed 12 July 2019)"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5442-6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.03.010"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.99"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.498"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb14159.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202133"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.10.006"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(95)01295-V"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2008.03.006"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1993.tb04205.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2169\/naika.96.1709"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)05303-8"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21422"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.120071"},{"key":"e_1_2_8_24_1","unstructured":"PubChem(2005).3 4\u2010Diaminopyridine.https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/3_4\u2010diaminopyridine(accessed 12 July 2019)"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11022.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.065"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26052"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.603"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90893-3"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90322-3"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12218"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.025"},{"issue":"1","key":"e_1_2_8_33_1","first-page":"76","article-title":"A case of Lambert\u2010Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4\u2010diaminopyridine","volume":"47","author":"Uekita K.","year":"2009","journal-title":"Nihon Koky\u016bki Gakkai Zasshi"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-009-0010-z"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.35"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062109"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001800200117"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bdd.2203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.2203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T03:04:21Z","timestamp":1694315061000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.2203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/bdd.2203"],"URL":"https:\/\/doi.org\/10.1002\/bdd.2203","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"2019-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}